Navigation Links
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Date:3/11/2009

te into our Phase 3 development plan. We believe such endpoints are the only critical and relevant primary endpoints for Phase 3 trials in patients with CRPC and for ultimately achieving marketing approval."

Results from our Phase 2 clinical development program are summarized below:

    -   First Line Prostate Cancer Potential Survival Advantage - longer
        survival duration, estimated at 10.6 months, in a randomized Phase 2
        clinical trial of OGX-011 in combination with docetaxel and
        prednisone ("the OGX-011 arm") when compared to docetaxel alone ("the
        control arm") for first-line treatment of metastatic CRPC. The median
        survival was 27.5 months for the patients in the OGX-011 arm and 16.9
        months for those in the control arm. Results currently indicate that
        patients in the OGX-011 arm have a death rate of approximately 40%
        lower than patients in the control arm. Additional survival updates
        are needed before a mature median survival for the OGX-011 arm can be
        reported; however, based on the current results, OncoGenex has
        calculated that the final median survival for patients in the OGX-011
        arm cannot be lower than 22.7 months, representing at least a 5.8
        month median survival benefit. For comparison, docetaxel was approved
        for treatment of metastatic CRPC by the FDA based on a survival
        advantage of 2.4 months over mitoxantrone.

    -   Second Line Prostate Cancer Potential Survival Advantage - longer
        than expected survival durations for patients receiving OGX-011 in
        combination with either mitoxantrone or docetaxel retreatment as
        second-line chemotherapy as compared to reported survival durations
        in two published studies of CRPC patients receiving second-line
        chemotherapy. As of January 14, 2009, the median survival duration
        for the randomized 20 patien
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... LayerBio is an MIT spin-off developing novel ... National Eye Institute (NEI) at the National Institutes of ... grant to develop a drug-eluting intraocular lens (IOL) for ... of vision loss in people over age 40 and ... Ken Mandell, LayerBio’s Founder and CEO, "There is a ...
(Date:12/19/2014)... In contrast to traditional LED lights where the ... uses proprietary LED technology to incorporate their spectra in ... is critical in low proximity installations. The Valoya L-series ... lifetime which is up to four times longer than ... cost was clearly higher when compared to traditional fluorescent ...
(Date:12/19/2014)... Egenix, Inc. is pleased to announce that Lionel Goldfrank ... succeed Donald Fresne ; Mr. Fresne has also resigned ... of the Board.  In recognition of the many contributions and ... twenty years, the Board designated Mr. Fresne as Chairman Emeritus. ... Search Committee to find a suitable replacement with Biotech industry ...
(Date:12/17/2014)... Based on the revenues gained ... market is dominated by four major players contributing ... These players include GE Healthcare (U.K.), Siemens AG ... , Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html ... be attributed to its strong product portfolio, which ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... (Nasdaq: VRUS ), a clinical stage pharmaceutical ... to treat viral infections, reported financial results and operational ... Financial Results Revenues were $1.9 million during the ... for the quarter ended March 31, 2008 and reflect ...
... Iceland, May 11 deCODE genetics,(Nasdaq: DCGN ) ... March 31, 2009. A conference call to discuss these ... webcast live tomorrow,Tuesday, May 12, at 8:00am Eastern Daylight ... Net loss for the quarter ended ...
... MOUNTAIN VIEW, Calif., May 11 VIVUS, Inc. (Nasdaq: ... and commercialization of novel therapeutic products, today reported its highlights and ... First Quarter 2009 Highlights: , ... European Patent for Qnexa - In January 2009, we announced ...
Cached Biology Technology:Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 2Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 3Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 4Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 5Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 6Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 7Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 8deCODE genetics Announces First Quarter 2009 Financial Results 2deCODE genetics Announces First Quarter 2009 Financial Results 3deCODE genetics Announces First Quarter 2009 Financial Results 4deCODE genetics Announces First Quarter 2009 Financial Results 5deCODE genetics Announces First Quarter 2009 Financial Results 6deCODE genetics Announces First Quarter 2009 Financial Results 7deCODE genetics Announces First Quarter 2009 Financial Results 8VIVUS Reports First Quarter 2009 Financial Results and Highlights 2VIVUS Reports First Quarter 2009 Financial Results and Highlights 3VIVUS Reports First Quarter 2009 Financial Results and Highlights 4VIVUS Reports First Quarter 2009 Financial Results and Highlights 5VIVUS Reports First Quarter 2009 Financial Results and Highlights 6VIVUS Reports First Quarter 2009 Financial Results and Highlights 7
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... A molecule that helps the body's motor nerve cells ... a major role in inhibiting spinal-cord neurons from regenerating ... found. In cultured cells, the researchers found that a ... stabilizes long nerve fibers in adult vertebrates ?chemically blocks ...
... researchers first to report function of tunneling nanotubules , ... an extensive network of tiny tunnels that, like a ... signals to distant cells. This surprising discovery, being reported ... in the September issue of the journal Immunity, may ...
... seeking ways to eliminate pollution from waterways with microbes ... freshwater ponds can generate electricity. They present their findings ... Society for Microbiology. , "The bacteria are capable of ... to operate small electronic devices. As long as the ...
Cached Biology News:Researchers find molecule that inhibits regrowth of spinal nerve cells 2Researchers find molecule that inhibits regrowth of spinal nerve cells 3'Underground' tunnels discovered as means for communication between immune system cells 2'Underground' tunnels discovered as means for communication between immune system cells 3'Underground' tunnels discovered as means for communication between immune system cells 4Pollution-eating bacteria produce electricity 2
... siRNA library screening, optimal siRNA ... and verified for each cell ... siRNA Transfection Optimization Kit, which ... transfection conditions in 96 well ...
... Series of positioning slides offers multiple ... leadscrew, micrometer, and manual. With this ... cost-effective multi-axis systems. These slides also ... resolutions down to 10 nanometers, integrated ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
Biology Products: